Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1629-1637

  Yang, Joy C ^a   Bai, Lanfang ^a   Yap, Stanley ^a   Gao, Allen C ^a,b   Kung, Hsing Jien ^a,b   Evans, Christopher P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; GELATINASE B; INTERLEUKIN 8; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; CANCER INHIBITION; CELL GROWTH; CELL INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIOXOLES; BONE AND BONES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; NEOPLASM INVASIVENESS; OSTEOCLASTS; OSTEOGENESIS; OSTEOLYSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANK LIGAND; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953455677     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1058     Document Type: Article

References (47)

1. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathol 2000;31:578-83. (Pubitemid 30323983)
2. Keller ET, Zhang J, Cooper CR, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001;20:333-49. (Pubitemid 34595275)
3. Roato I, D'Amelio P, Gorassini E, et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS ONE 2008;3:e3627.
4. Inoue H, Nishimura K, Oka D, et al. Prostate cancer mediates osteoclastogenesis through two different pathways. Cancer Lett 2005;223:121-8. (Pubitemid 40693716)
5. Whang PG, Schwarz EM, Gamradt SC, Dougall WC, Lieberman JR. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res 2005;23:1475-83.
6. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Cancer Res 2003;63:7883-90.
7. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992;90:1622-7.
8. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693-702.
9. Insogna KL, Sahni M, Grey AB, et al. Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. J Clin Invest 1997;100:2476-85.
10. Miyazaki T, Sanjay A, Neff L, Tanaka S, Horne WC, Baron R. Src kinase activity is essential for osteoclast function. J Biol Chem 2004;279:17660-6. (Pubitemid 38560531)
11. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κb and c-Jun N-terminal kinase. J Biol Chem 1998;273:20551-5.
12. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J Biol Chem 1998;273:34120-7. (Pubitemid 129758357)
13. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-5. (Pubitemid 29168945)
14. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 1997;3:1285-9. (Pubitemid 27508833)
15. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002;115:4317-25. (Pubitemid 35460702)
16. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem 2000;275:31155-61.
17. Wagner EF. Functions of AP1 (Fos/Jun) in bone development. Ann Rheum Dis 2002;61 Suppl 2:ii40-2.
18. Koga S, Yogo K, Yoshikawa K, et al. Physical and functional association of c-Src and adhesion and degranulation promoting adaptor protein (ADAP) in osteoclastogenesis in vitro. J Biol Chem 2005;280:31564-71. (Pubitemid 41291900)
19. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4. (Pubitemid 27415705)
20. Xing L, Venegas AM, Chen A, et al. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev 2001;15:241-53. (Pubitemid 32107668)
21. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003;10:1165-77. (Pubitemid 37258582)
22. Sugatani T, Hruska KA. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005;280:3583-9. (Pubitemid 40223824)
23. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia (New York, NY) 2007;9:90-100.
24. Guo Z, Dai B, Jiang T, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10:309-19. (Pubitemid 44512189)
25. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001;21:8385-97.
26. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP. Aberrant activation of androgen receptor in a new neuropeptideautocrine model of androgen-insensitive prostate cancer. Cancer Res 2009;69:151-60.
27. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009;15:3540-9.
28. Lochter A, Srebrow A, Sympson CJ, Terracio N, Werb Z, Bissell MJ. Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J Biol Chem 1997;272:5007-15. (Pubitemid 27090053)
29. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27:6365-75.
30. Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Redini F. DU145 human prostate cancer cells express functional receptor activator of NFκB: new insights in the prostate cancer bone metastasis process. Bone 2007;40:981-90. (Pubitemid 46386537)
31. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003;9:1200-10. (Pubitemid 36323730)
32. Lee YP, Schwarz EM, Davies M, et al. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 2002;62:5564-70.
33. Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 2005;65:8818-25. (Pubitemid 41377370)
34. Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004;4:308-18.
35. Kopetz S, Shah AN, Gallick GE. Src continues aging: current and future clinical directions. Clin Cancer Res 2007;13:7232-6.
36. Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 2009;103:434-40.
37. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007;67:1580-8. (Pubitemid 46383382)
38. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9. (Pubitemid 41507982)
39. Park SI, Gallick GE. c-Src activation in the tumor-associated endothelial cells contributes to the lymph node metastases of prostate cancer cells. Proc Am Assoc Cancer Res 2007;48:3002.
40. de Vries TJ, Mullender MG, van Duin MA, et al. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res 2009;7:476-88.
41. Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16:67-78.
42. Hannon RA, Clack G, Rimmer M, et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial. J Bone Miner Res 2010;25:463-71.
43. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009;101:263-8.
44. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002;1602:114-30.
45. Myoui A, Nishimura R, Williams PJ, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63:5028-33. (Pubitemid 37022641)
46. Wu Z, Chang P-C, Yang JC, et al. Autophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitors. Genes Cancer 2010;1:40-9.
47. Suh J, Rabson AB. NF-κB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004;91:100-17.